Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Foy
2. Gabexate Mesilate
3. Gabexate Mesylate
4. Gabexate Methanesulfonate
5. Gabexate Monomethanesulfonate
6. Gabexate Monomethanesulfonate, 14c Labeled Cpd
7. Gabexate Monomethanesulfonate, 14c-labeled Cpd
8. Mesilate, Gabexate
9. Mesylate, Gabexate
10. Methanesulfonate, Gabexate
11. Monomethanesulfonate, Gabexate
1. 39492-01-8
2. Gabexate [inn]
3. Ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate
4. Chembl87563
5. Ethyl P-hydroxybenzoate 6-guanidinohexanoate
6. Gabexate (inn)
7. 4v7m9137x9
8. Gabexato
9. Gabexatum
10. Gabexatum [inn-latin]
11. Gabexato [inn-spanish]
12. Methanesulfonic Acid Ethyl 4-[(6-carbamimidamidohexanoyl)oxy]benzoate
13. Unii-4v7m9137x9
14. Gabexate [jan]
15. Gabexate [mi]
16. Prestwick0_001008
17. Prestwick1_001008
18. Prestwick2_001008
19. Prestwick3_001008
20. Gabexate [who-dd]
21. Benzoic Acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, Ethyl Ester
22. Bspbio_001135
23. Schembl446024
24. Spbio_003016
25. Bpbio1_001249
26. Gtpl7863
27. Dtxsid9048566
28. Schembl13287301
29. Chebi:93036
30. Zinc2002226
31. Bdbm50104435
32. Db12831
33. Ethyl 4-(6-guanidinohexanoyloxy)benzoate
34. Ncgc00025297-01
35. Ncgc00025297-02
36. Ncgc00025297-10
37. Ls-14525
38. Sbi-0207080.p001
39. Ethyl 4-((6-guanidinohexanoyl)oxy)benzoate
40. Ethyl-p-(6-guanidinohex-anoyloxy)-benzoate
41. Ab00513998
42. D08004
43. Ab00513998_02
44. Q5515384
45. 4-(6-guanidino-hexanoyloxy)-benzoic Acid Ethyl Ester
46. Brd-k59256312-066-03-3
47. Ethyl 4-({6-[(diaminomethylidene)amino]hexanoyl}oxy)benzoate
48. 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic Acid Ethyl Ester
| Molecular Weight | 321.37 g/mol |
|---|---|
| Molecular Formula | C16H23N3O4 |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 11 |
| Exact Mass | 321.16885622 g/mol |
| Monoisotopic Mass | 321.16885622 g/mol |
| Topological Polar Surface Area | 117 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 400 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
No approved indication.
Gabexate bind and inhibits serine proteases in the coagulation cascade to prevent blood clotting. It also prevents proteolytic destruction of IkappaB resulting in suppression of the nuclear factor kappa-B signalling pathway. Ultimately this decreases the production of inflammatory cytokines such as tumor necrosis factor alpha which are produced as a result of NFkappaB activation.
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Serine Proteinase Inhibitors
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)
Gabexate inhibits kallikrein, plasmin, and thrombin by binding to their active sites. The inhibition of these components of the coagulation cascade ultimately prevents the formation of fibrin which must be present and polymerized to form a clot. Gabexate decreases the production of inflammatory cytokines by attenuating NFkappaB and c-Jun N-terminal kinase (JNK) pathway activity. The exact mechanism for this is unknown but it is thought that gabexate prevents the proteolyytic destruction of IkappaB which deactivates NFkappaB and interferes with activator protein 1 binding to DNA.
ABOUT THIS PAGE
A Gabexato manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gabexato, including repackagers and relabelers. The FDA regulates Gabexato manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gabexato API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gabexato supplier is an individual or a company that provides Gabexato active pharmaceutical ingredient (API) or Gabexato finished formulations upon request. The Gabexato suppliers may include Gabexato API manufacturers, exporters, distributors and traders.
click here to find a list of Gabexato suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Gabexato Drug Master File in Japan (Gabexato JDMF) empowers Gabexato API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Gabexato JDMF during the approval evaluation for pharmaceutical products. At the time of Gabexato JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Gabexato suppliers with JDMF on PharmaCompass.
Gabexato Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gabexato GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gabexato GMP manufacturer or Gabexato GMP API supplier for your needs.
A Gabexato CoA (Certificate of Analysis) is a formal document that attests to Gabexato's compliance with Gabexato specifications and serves as a tool for batch-level quality control.
Gabexato CoA mostly includes findings from lab analyses of a specific batch. For each Gabexato CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gabexato may be tested according to a variety of international standards, such as European Pharmacopoeia (Gabexato EP), Gabexato JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gabexato USP).
LOOKING FOR A SUPPLIER?
